Uncategorized

2 items

June 11, 2026

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical
Agreement highlights Paragon’s ability to build companies around [...]
May 26, 2026

JAMA Neurology Publishes Phase 3 Data on D1 Receptor Antagonist Ecopipam in Tourette Syndrome
Phase 3 data show delayed time to relapse [...]